Bristol Myers Squibb CO Form 4 insider transactions

Bristol Myers Squibb Director Paula A. Price acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership.

Bristol-Myers Squibb Director Michael R. McMullen acquired 3,996.367 deferred share units, increasing his beneficial ownership to 14,979.689 units.

Bristol-Myers Squibb Director Manuel Hidalgo Medina acquired 3,996.367 Deferred Share Units, increasing his beneficial ownership.

Bristol Myers Squibb Director Julia A Haller acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership to 37,903.154 units.

Bristol Myers Squibb Director Deepak Bhatt acquired 3,996.367 Deferred Share Units at $55.05 each, increasing his beneficial ownership to 19,241.818 units.

Bristol-Myers Squibb Director Peter J. Arduini acquired 3,996.367 Deferred Share Units, increasing his beneficial ownership.

Bristol Myers Squibb director Phyllis R. Yale acquired 648.869 deferred share units as part of her compensation plan, increasing her total beneficial ownership to 38,891.933 units.

A director at Bristol-Myers Squibb Company acquired 926.956 Deferred Share Units as part of a compensation plan.

Bristol-Myers Squibb Director Derica W. Rice acquired 695.217 Deferred Share Units, increasing total beneficial ownership to 34,934.653 units.

Bristol Myers Squibb Director Michael R. McMullen acquired 648.869 Deferred Share Units, increasing his beneficial ownership to 10,860.897 units.

Bristol-Myers Squibb Director Peter J. Arduini is set to acquire 625.695 deferred share units in a pre-planned transaction.

Bristol-Myers Squibb's EVP, Chief Commercial Officer, Adam Lenkowsky, acquired 22,568 restricted stock units, vesting over three years.

Bristol-Myers Squibb CEO Christopher S. Boerner reported the vesting of market share units and related stock transactions, including tax withholdings and a performance-based adjustment.

Bristol-Myers Squibb EVP Gregory Scott Meyers reported the vesting of 6,281 restricted stock units and the sale of 2,665 shares for tax purposes.

Karin Shanahan, EVP at Bristol-Myers Squibb, saw restricted stock units vest and sold shares to cover tax obligations.

Bristol-Myers Squibb's EVP, General Counsel, Cari Gallman, reported the acquisition of common stock through RSU vesting and subsequent tax-related share disposition.

Bristol Myers Squibb Director Phyllis R. Yale acquired 776.053 Deferred Share Units, increasing her beneficial ownership to 37,734.687 units.

Theodore R. Samuels II, a director at Bristol Myers Squibb, acquired 1,108.647 Deferred Share Units as part of his compensation.

Bristol-Myers Squibb Director Derica W. Rice acquired 831.486 Deferred Share Units as part of her compensation, increasing her total beneficial ownership to 33,784.279 units.

Bristol-Myers Squibb Director Michael R. McMullen increased his beneficial ownership of Deferred Share Units by 776.053 units on September 30, 2025, as part of a pre-arranged plan.

Bristol-Myers Squibb Director Peter J. Arduini acquired 748.337 Deferred Share Units, increasing his total beneficial ownership to 64,620.164 units.

Bristol-Myers Squibb's EVP and CFO, David V. Elkins, sold 56,000 shares of common stock for $47.33 per share, executed under a pre-arranged 10b5-1 trading plan.

A Bristol-Myers Squibb executive reported a future transaction under a 10b5-1 plan involving RSU conversion and tax-related share sale.

Bristol Myers Squibb's EVP, Chief Medical Officer, and Head of Development, Cristian Massacesi, was granted 204,691 restricted stock units.

Bristol-Myers Squibb EVP Cari Gallman reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Bristol Myers Squibb's EVP of Corporate Affairs, Wendy Short Bartie, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Bristol Myers Squibb's EVP and Chief Strategy Officer, Hiroshi Chris Shibutani, was granted 12,810 restricted stock units, vesting over three years.

Bristol-Myers Squibb Director Peter J. Arduini acquired 729.099 Deferred Share Units, increasing his beneficial ownership to 62,988.874 units, as part of deferred compensation and reinvested dividends.

Bristol-Myers Squibb Company's Director, Michael R. McMullen, was granted 728.359 Deferred Share Units as part of his compensation, increasing his total beneficial ownership to 9,171.659 units.

Bristol-Myers Squibb Company Director Derica W. Rice has acquired 810.11 Deferred Share Units, increasing her beneficial ownership to 32,497.258 units.